JP2009523165A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009523165A5 JP2009523165A5 JP2008549960A JP2008549960A JP2009523165A5 JP 2009523165 A5 JP2009523165 A5 JP 2009523165A5 JP 2008549960 A JP2008549960 A JP 2008549960A JP 2008549960 A JP2008549960 A JP 2008549960A JP 2009523165 A5 JP2009523165 A5 JP 2009523165A5
- Authority
- JP
- Japan
- Prior art keywords
- hydroxy
- methyl
- propyl
- isobutyl
- thiophen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 22
- 239000001257 hydrogen Substances 0.000 claims 22
- -1 2,3-dihydroxypropyl Chemical group 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 21
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 10
- 150000002431 hydrogen Chemical class 0.000 claims 10
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 4
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 3
- 150000003577 thiophenes Chemical class 0.000 claims 3
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000006533 methyl amino methyl group Chemical group [H]N(C([H])([H])[H])C([H])([H])* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 229930192474 thiophene Natural products 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- MDCUXJSPWVQNNI-UHFFFAOYSA-N 1-[3,4-bis(2-methylpropyl)thiophen-2-yl]-3-(4-hydroxy-3,5-dimethylphenyl)propan-1-one Chemical compound CC(C)CC1=CSC(C(=O)CCC=2C=C(C)C(O)=C(C)C=2)=C1CC(C)C MDCUXJSPWVQNNI-UHFFFAOYSA-N 0.000 claims 1
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 claims 1
- ADAPMLGFQADHTG-UHFFFAOYSA-N 2-hydroxy-n-[2-hydroxy-3-[3-methoxy-4-[5-[5-methyl-4-(2-methylpropyl)thiophen-2-yl]-1,2,4-oxadiazol-3-yl]phenoxy]propyl]acetamide Chemical compound COC1=CC(OCC(O)CNC(=O)CO)=CC=C1C1=NOC(C=2SC(C)=C(CC(C)C)C=2)=N1 ADAPMLGFQADHTG-UHFFFAOYSA-N 0.000 claims 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- SSCJNSUMOPTRAW-UHFFFAOYSA-N 3-[2,6-dimethyl-4-[5-[3-methyl-4-(2-methylpropyl)thiophen-2-yl]-1,3,4-oxadiazol-2-yl]phenoxy]propane-1,2-diol Chemical compound CC(C)CC1=CSC(C=2OC(=NN=2)C=2C=C(C)C(OCC(O)CO)=C(C)C=2)=C1C SSCJNSUMOPTRAW-UHFFFAOYSA-N 0.000 claims 1
- FTBUJOHYQKNAMC-UHFFFAOYSA-N 3-[2,6-dimethyl-4-[5-[4-(2-methylpropyl)-3-propylthiophen-2-yl]-1,3,4-oxadiazol-2-yl]phenoxy]propane-1,2-diol Chemical compound CC(C)CC1=CSC(C=2OC(=NN=2)C=2C=C(C)C(OCC(O)CO)=C(C)C=2)=C1CCC FTBUJOHYQKNAMC-UHFFFAOYSA-N 0.000 claims 1
- WOTLDRBDHUXWGE-UHFFFAOYSA-N 3-[2-ethyl-6-methyl-4-[5-[5-methyl-4-(2-methylpropyl)thiophen-2-yl]-1,2,4-oxadiazol-3-yl]phenyl]-n-(2-hydroxyethyl)propanamide Chemical compound CC1=C(CCC(=O)NCCO)C(CC)=CC(C=2N=C(ON=2)C=2SC(C)=C(CC(C)C)C=2)=C1 WOTLDRBDHUXWGE-UHFFFAOYSA-N 0.000 claims 1
- JCSASMVQZOFEIX-UHFFFAOYSA-N 3-[3-methoxy-4-[5-[5-methyl-4-(2-methylpropyl)thiophen-2-yl]-1,2,4-oxadiazol-3-yl]phenoxy]propane-1,2-diol Chemical compound COC1=CC(OCC(O)CO)=CC=C1C1=NOC(C=2SC(C)=C(CC(C)C)C=2)=N1 JCSASMVQZOFEIX-UHFFFAOYSA-N 0.000 claims 1
- QEBITTLCNFUSAJ-FQEVSTJZSA-N 3-[4-[(2s)-2,3-dihydroxypropoxy]-3,5-dimethylphenyl]-1-[3,5-dimethyl-4-(2-methylpropyl)thiophen-2-yl]propan-1-one Chemical compound CC(C)CC1=C(C)SC(C(=O)CCC=2C=C(C)C(OC[C@@H](O)CO)=C(C)C=2)=C1C QEBITTLCNFUSAJ-FQEVSTJZSA-N 0.000 claims 1
- AIJDEIUQEPLWKG-NRFANRHFSA-N 3-[4-[(2s)-2,3-dihydroxypropoxy]-3,5-dimethylphenyl]-1-[4-(2-methylpropyl)-3-propylthiophen-2-yl]propan-1-one Chemical compound CC(C)CC1=CSC(C(=O)CCC=2C=C(C)C(OC[C@@H](O)CO)=C(C)C=2)=C1CCC AIJDEIUQEPLWKG-NRFANRHFSA-N 0.000 claims 1
- YAQLSHRLKQDLQB-UHFFFAOYSA-N 3-[4-[5-[3,4-bis(2-methylpropyl)thiophen-2-yl]-1,3,4-oxadiazol-2-yl]-2,6-dimethylphenoxy]propane-1,2-diol Chemical compound CC(C)CC1=CSC(C=2OC(=NN=2)C=2C=C(C)C(OCC(O)CO)=C(C)C=2)=C1CC(C)C YAQLSHRLKQDLQB-UHFFFAOYSA-N 0.000 claims 1
- QQXYBEPBLKPJKL-UHFFFAOYSA-N 3-[4-[5-[3-ethyl-4-(2-methylpropyl)thiophen-2-yl]-1,3,4-oxadiazol-2-yl]-2,6-dimethylphenoxy]propane-1,2-diol Chemical compound CC(C)CC1=CSC(C=2OC(=NN=2)C=2C=C(C)C(OCC(O)CO)=C(C)C=2)=C1CC QQXYBEPBLKPJKL-UHFFFAOYSA-N 0.000 claims 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 claims 1
- 208000012657 Atopic disease Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 1
- 210000004087 cornea Anatomy 0.000 claims 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- HOKNQKALAQXVLW-UHFFFAOYSA-N n-(1,3-dihydroxypropan-2-yl)-3-[2,6-dimethyl-4-[5-[5-methyl-4-(2-methylpropyl)thiophen-2-yl]-1,3,4-oxadiazol-2-yl]phenyl]propanamide Chemical compound S1C(C)=C(CC(C)C)C=C1C1=NN=C(C=2C=C(C)C(CCC(=O)NC(CO)CO)=C(C)C=2)O1 HOKNQKALAQXVLW-UHFFFAOYSA-N 0.000 claims 1
- JGDQODJFFAUBNE-OAQYLSRUSA-N n-[(2r)-3-[2,6-diethyl-4-[5-[3-methyl-4-(2-methylpropyl)thiophen-2-yl]-1,2,4-oxadiazol-3-yl]phenoxy]-2-hydroxypropyl]-2-hydroxyacetamide Chemical compound CCC1=C(OC[C@H](O)CNC(=O)CO)C(CC)=CC(C=2N=C(ON=2)C2=C(C(CC(C)C)=CS2)C)=C1 JGDQODJFFAUBNE-OAQYLSRUSA-N 0.000 claims 1
- IJHGLOHZTVMLBN-LJQANCHMSA-N n-[(2r)-3-[2,6-dimethyl-4-[3-[3-methyl-4-(2-methylpropyl)thiophen-2-yl]-1,2,4-oxadiazol-5-yl]phenoxy]-2-hydroxypropyl]-2-hydroxyacetamide Chemical compound CC(C)CC1=CSC(C=2N=C(ON=2)C=2C=C(C)C(OC[C@H](O)CNC(=O)CO)=C(C)C=2)=C1C IJHGLOHZTVMLBN-LJQANCHMSA-N 0.000 claims 1
- OVKKFHCTLCSFTN-LJQANCHMSA-N n-[(2r)-3-[2,6-dimethyl-4-[5-[3-methyl-4-(2-methylpropyl)thiophen-2-yl]-1,2,4-oxadiazol-3-yl]phenoxy]-2-hydroxypropyl]-2-hydroxyacetamide Chemical compound CC(C)CC1=CSC(C=2ON=C(N=2)C=2C=C(C)C(OC[C@H](O)CNC(=O)CO)=C(C)C=2)=C1C OVKKFHCTLCSFTN-LJQANCHMSA-N 0.000 claims 1
- OFOVTHUPNHDXOT-LJQANCHMSA-N n-[(2r)-3-[2,6-dimethyl-4-[5-[5-methyl-4-(2-methylpropyl)thiophen-2-yl]-1,3,4-oxadiazol-2-yl]phenoxy]-2-hydroxypropyl]-2-hydroxyacetamide Chemical compound S1C(C)=C(CC(C)C)C=C1C1=NN=C(C=2C=C(C)C(OC[C@H](O)CNC(=O)CO)=C(C)C=2)O1 OFOVTHUPNHDXOT-LJQANCHMSA-N 0.000 claims 1
- IUNDDHWOOJLJCV-QGZVFWFLSA-N n-[(2r)-3-[2-chloro-4-[5-[3,5-dimethyl-4-(2-methylpropyl)thiophen-2-yl]-1,2,4-oxadiazol-3-yl]-6-methylphenoxy]-2-hydroxypropyl]-2-hydroxyacetamide Chemical compound CC(C)CC1=C(C)SC(C=2ON=C(N=2)C=2C=C(Cl)C(OC[C@H](O)CNC(=O)CO)=C(C)C=2)=C1C IUNDDHWOOJLJCV-QGZVFWFLSA-N 0.000 claims 1
- OUIIFEXFZFIDFR-QGZVFWFLSA-N n-[(2r)-3-[2-chloro-6-methyl-4-[5-[3-methyl-4-(2-methylpropyl)thiophen-2-yl]-1,2,4-oxadiazol-3-yl]phenoxy]-2-hydroxypropyl]-2-hydroxyacetamide Chemical compound CC(C)CC1=CSC(C=2ON=C(N=2)C=2C=C(Cl)C(OC[C@H](O)CNC(=O)CO)=C(C)C=2)=C1C OUIIFEXFZFIDFR-QGZVFWFLSA-N 0.000 claims 1
- UULCTKWNLBKDEG-QGZVFWFLSA-N n-[(2r)-3-[2-chloro-6-methyl-4-[5-[5-methyl-4-(2-methylpropyl)thiophen-2-yl]-1,2,4-oxadiazol-3-yl]phenoxy]-2-hydroxypropyl]-2-hydroxyacetamide Chemical compound S1C(C)=C(CC(C)C)C=C1C1=NC(C=2C=C(Cl)C(OC[C@H](O)CNC(=O)CO)=C(C)C=2)=NO1 UULCTKWNLBKDEG-QGZVFWFLSA-N 0.000 claims 1
- USMRGOCLFZPFTE-HXUWFJFHSA-N n-[(2r)-3-[2-ethyl-6-methyl-4-[5-[3-methyl-4-(2-methylpropyl)thiophen-2-yl]-1,2,4-oxadiazol-3-yl]phenoxy]-2-hydroxypropyl]-2-hydroxyacetamide Chemical compound CC1=C(OC[C@H](O)CNC(=O)CO)C(CC)=CC(C=2N=C(ON=2)C2=C(C(CC(C)C)=CS2)C)=C1 USMRGOCLFZPFTE-HXUWFJFHSA-N 0.000 claims 1
- NSTPEVOOVPYRJA-HXUWFJFHSA-N n-[(2r)-3-[2-ethyl-6-methyl-4-[5-[3-methyl-4-(2-methylpropyl)thiophen-2-yl]-1,3,4-oxadiazol-2-yl]phenoxy]-2-hydroxypropyl]-2-hydroxyacetamide Chemical compound CC1=C(OC[C@H](O)CNC(=O)CO)C(CC)=CC(C=2OC(=NN=2)C2=C(C(CC(C)C)=CS2)C)=C1 NSTPEVOOVPYRJA-HXUWFJFHSA-N 0.000 claims 1
- LQLUYMABVCWDQL-HXUWFJFHSA-N n-[(2r)-3-[2-ethyl-6-methyl-4-[5-[5-methyl-4-(2-methylpropyl)thiophen-2-yl]-1,3,4-oxadiazol-2-yl]phenoxy]-2-hydroxypropyl]-2-hydroxyacetamide Chemical compound CC1=C(OC[C@H](O)CNC(=O)CO)C(CC)=CC(C=2OC(=NN=2)C=2SC(C)=C(CC(C)C)C=2)=C1 LQLUYMABVCWDQL-HXUWFJFHSA-N 0.000 claims 1
- OYISSSFCGPOJML-OAQYLSRUSA-N n-[(2r)-3-[4-[3-[3,5-dimethyl-4-(2-methylpropyl)thiophen-2-yl]-3-oxopropyl]-2,6-dimethylphenoxy]-2-hydroxypropyl]-2-hydroxyacetamide Chemical compound CC(C)CC1=C(C)SC(C(=O)CCC=2C=C(C)C(OC[C@H](O)CNC(=O)CO)=C(C)C=2)=C1C OYISSSFCGPOJML-OAQYLSRUSA-N 0.000 claims 1
- ZTSWVCLWOFEETE-JOCHJYFZSA-N n-[(2r)-3-[4-[3-[3,5-dimethyl-4-(2-methylpropyl)thiophen-2-yl]-3-oxopropyl]-2-ethyl-6-methylphenoxy]-2-hydroxypropyl]-2-hydroxyacetamide Chemical compound CC1=C(OC[C@H](O)CNC(=O)CO)C(CC)=CC(CCC(=O)C2=C(C(CC(C)C)=C(C)S2)C)=C1 ZTSWVCLWOFEETE-JOCHJYFZSA-N 0.000 claims 1
- IEUWALCEEHWNIP-LJQANCHMSA-N n-[(2r)-3-[4-[5-[3,5-dimethyl-4-(2-methylpropyl)thiophen-2-yl]-1,3,4-oxadiazol-2-yl]-2,6-dimethylphenoxy]-2-hydroxypropyl]-2-hydroxyacetamide Chemical compound CC(C)CC1=C(C)SC(C=2OC(=NN=2)C=2C=C(C)C(OC[C@H](O)CNC(=O)CO)=C(C)C=2)=C1C IEUWALCEEHWNIP-LJQANCHMSA-N 0.000 claims 1
- DCEINVNNEWFREB-HXUWFJFHSA-N n-[(2r)-3-[4-[5-[3,5-dimethyl-4-(2-methylpropyl)thiophen-2-yl]-1,3,4-oxadiazol-2-yl]-2-ethyl-6-methylphenoxy]-2-hydroxypropyl]-2-hydroxyacetamide Chemical compound CC1=C(OC[C@H](O)CNC(=O)CO)C(CC)=CC(C=2OC(=NN=2)C2=C(C(CC(C)C)=C(C)S2)C)=C1 DCEINVNNEWFREB-HXUWFJFHSA-N 0.000 claims 1
- JGDQODJFFAUBNE-NRFANRHFSA-N n-[(2s)-3-[2,6-diethyl-4-[5-[3-methyl-4-(2-methylpropyl)thiophen-2-yl]-1,2,4-oxadiazol-3-yl]phenoxy]-2-hydroxypropyl]-2-hydroxyacetamide Chemical compound CCC1=C(OC[C@@H](O)CNC(=O)CO)C(CC)=CC(C=2N=C(ON=2)C2=C(C(CC(C)C)=CS2)C)=C1 JGDQODJFFAUBNE-NRFANRHFSA-N 0.000 claims 1
- RQJFRUJPEPUBJT-NRFANRHFSA-N n-[(2s)-3-[2,6-diethyl-4-[5-[5-methyl-4-(2-methylpropyl)thiophen-2-yl]-1,2,4-oxadiazol-3-yl]phenoxy]-2-hydroxypropyl]-2-hydroxyacetamide Chemical compound CCC1=C(OC[C@@H](O)CNC(=O)CO)C(CC)=CC(C=2N=C(ON=2)C=2SC(C)=C(CC(C)C)C=2)=C1 RQJFRUJPEPUBJT-NRFANRHFSA-N 0.000 claims 1
- IJHGLOHZTVMLBN-IBGZPJMESA-N n-[(2s)-3-[2,6-dimethyl-4-[3-[3-methyl-4-(2-methylpropyl)thiophen-2-yl]-1,2,4-oxadiazol-5-yl]phenoxy]-2-hydroxypropyl]-2-hydroxyacetamide Chemical compound CC(C)CC1=CSC(C=2N=C(ON=2)C=2C=C(C)C(OC[C@@H](O)CNC(=O)CO)=C(C)C=2)=C1C IJHGLOHZTVMLBN-IBGZPJMESA-N 0.000 claims 1
- OVKKFHCTLCSFTN-IBGZPJMESA-N n-[(2s)-3-[2,6-dimethyl-4-[5-[3-methyl-4-(2-methylpropyl)thiophen-2-yl]-1,2,4-oxadiazol-3-yl]phenoxy]-2-hydroxypropyl]-2-hydroxyacetamide Chemical compound CC(C)CC1=CSC(C=2ON=C(N=2)C=2C=C(C)C(OC[C@@H](O)CNC(=O)CO)=C(C)C=2)=C1C OVKKFHCTLCSFTN-IBGZPJMESA-N 0.000 claims 1
- OFOVTHUPNHDXOT-IBGZPJMESA-N n-[(2s)-3-[2,6-dimethyl-4-[5-[5-methyl-4-(2-methylpropyl)thiophen-2-yl]-1,3,4-oxadiazol-2-yl]phenoxy]-2-hydroxypropyl]-2-hydroxyacetamide Chemical compound S1C(C)=C(CC(C)C)C=C1C1=NN=C(C=2C=C(C)C(OC[C@@H](O)CNC(=O)CO)=C(C)C=2)O1 OFOVTHUPNHDXOT-IBGZPJMESA-N 0.000 claims 1
- IUNDDHWOOJLJCV-KRWDZBQOSA-N n-[(2s)-3-[2-chloro-4-[5-[3,5-dimethyl-4-(2-methylpropyl)thiophen-2-yl]-1,2,4-oxadiazol-3-yl]-6-methylphenoxy]-2-hydroxypropyl]-2-hydroxyacetamide Chemical compound CC(C)CC1=C(C)SC(C=2ON=C(N=2)C=2C=C(Cl)C(OC[C@@H](O)CNC(=O)CO)=C(C)C=2)=C1C IUNDDHWOOJLJCV-KRWDZBQOSA-N 0.000 claims 1
- OUIIFEXFZFIDFR-KRWDZBQOSA-N n-[(2s)-3-[2-chloro-6-methyl-4-[5-[3-methyl-4-(2-methylpropyl)thiophen-2-yl]-1,2,4-oxadiazol-3-yl]phenoxy]-2-hydroxypropyl]-2-hydroxyacetamide Chemical compound CC(C)CC1=CSC(C=2ON=C(N=2)C=2C=C(Cl)C(OC[C@@H](O)CNC(=O)CO)=C(C)C=2)=C1C OUIIFEXFZFIDFR-KRWDZBQOSA-N 0.000 claims 1
- UULCTKWNLBKDEG-KRWDZBQOSA-N n-[(2s)-3-[2-chloro-6-methyl-4-[5-[5-methyl-4-(2-methylpropyl)thiophen-2-yl]-1,2,4-oxadiazol-3-yl]phenoxy]-2-hydroxypropyl]-2-hydroxyacetamide Chemical compound S1C(C)=C(CC(C)C)C=C1C1=NC(C=2C=C(Cl)C(OC[C@@H](O)CNC(=O)CO)=C(C)C=2)=NO1 UULCTKWNLBKDEG-KRWDZBQOSA-N 0.000 claims 1
- USMRGOCLFZPFTE-FQEVSTJZSA-N n-[(2s)-3-[2-ethyl-6-methyl-4-[5-[3-methyl-4-(2-methylpropyl)thiophen-2-yl]-1,2,4-oxadiazol-3-yl]phenoxy]-2-hydroxypropyl]-2-hydroxyacetamide Chemical compound CC1=C(OC[C@@H](O)CNC(=O)CO)C(CC)=CC(C=2N=C(ON=2)C2=C(C(CC(C)C)=CS2)C)=C1 USMRGOCLFZPFTE-FQEVSTJZSA-N 0.000 claims 1
- NSTPEVOOVPYRJA-FQEVSTJZSA-N n-[(2s)-3-[2-ethyl-6-methyl-4-[5-[3-methyl-4-(2-methylpropyl)thiophen-2-yl]-1,3,4-oxadiazol-2-yl]phenoxy]-2-hydroxypropyl]-2-hydroxyacetamide Chemical compound CC1=C(OC[C@@H](O)CNC(=O)CO)C(CC)=CC(C=2OC(=NN=2)C2=C(C(CC(C)C)=CS2)C)=C1 NSTPEVOOVPYRJA-FQEVSTJZSA-N 0.000 claims 1
- LQLUYMABVCWDQL-FQEVSTJZSA-N n-[(2s)-3-[2-ethyl-6-methyl-4-[5-[5-methyl-4-(2-methylpropyl)thiophen-2-yl]-1,3,4-oxadiazol-2-yl]phenoxy]-2-hydroxypropyl]-2-hydroxyacetamide Chemical compound CC1=C(OC[C@@H](O)CNC(=O)CO)C(CC)=CC(C=2OC(=NN=2)C=2SC(C)=C(CC(C)C)C=2)=C1 LQLUYMABVCWDQL-FQEVSTJZSA-N 0.000 claims 1
- OYISSSFCGPOJML-NRFANRHFSA-N n-[(2s)-3-[4-[3-[3,5-dimethyl-4-(2-methylpropyl)thiophen-2-yl]-3-oxopropyl]-2,6-dimethylphenoxy]-2-hydroxypropyl]-2-hydroxyacetamide Chemical compound CC(C)CC1=C(C)SC(C(=O)CCC=2C=C(C)C(OC[C@@H](O)CNC(=O)CO)=C(C)C=2)=C1C OYISSSFCGPOJML-NRFANRHFSA-N 0.000 claims 1
- ZTSWVCLWOFEETE-QFIPXVFZSA-N n-[(2s)-3-[4-[3-[3,5-dimethyl-4-(2-methylpropyl)thiophen-2-yl]-3-oxopropyl]-2-ethyl-6-methylphenoxy]-2-hydroxypropyl]-2-hydroxyacetamide Chemical compound CC1=C(OC[C@@H](O)CNC(=O)CO)C(CC)=CC(CCC(=O)C2=C(C(CC(C)C)=C(C)S2)C)=C1 ZTSWVCLWOFEETE-QFIPXVFZSA-N 0.000 claims 1
- IEUWALCEEHWNIP-IBGZPJMESA-N n-[(2s)-3-[4-[5-[3,5-dimethyl-4-(2-methylpropyl)thiophen-2-yl]-1,3,4-oxadiazol-2-yl]-2,6-dimethylphenoxy]-2-hydroxypropyl]-2-hydroxyacetamide Chemical compound CC(C)CC1=C(C)SC(C=2OC(=NN=2)C=2C=C(C)C(OC[C@@H](O)CNC(=O)CO)=C(C)C=2)=C1C IEUWALCEEHWNIP-IBGZPJMESA-N 0.000 claims 1
- DCEINVNNEWFREB-FQEVSTJZSA-N n-[(2s)-3-[4-[5-[3,5-dimethyl-4-(2-methylpropyl)thiophen-2-yl]-1,3,4-oxadiazol-2-yl]-2-ethyl-6-methylphenoxy]-2-hydroxypropyl]-2-hydroxyacetamide Chemical compound CC1=C(OC[C@@H](O)CNC(=O)CO)C(CC)=CC(C=2OC(=NN=2)C2=C(C(CC(C)C)=C(C)S2)C)=C1 DCEINVNNEWFREB-FQEVSTJZSA-N 0.000 claims 1
- FBRBFSOXYFREET-UHFFFAOYSA-N n-[3-[2,6-dimethyl-4-[3-[4-(2-methylpropyl)-3-propylthiophen-2-yl]-3-oxopropyl]phenoxy]-2-hydroxypropyl]-2-hydroxyacetamide Chemical compound CC(C)CC1=CSC(C(=O)CCC=2C=C(C)C(OCC(O)CNC(=O)CO)=C(C)C=2)=C1CCC FBRBFSOXYFREET-UHFFFAOYSA-N 0.000 claims 1
- WZOXUNBBCJSFKL-UHFFFAOYSA-N n-[3-[2,6-dimethyl-4-[5-[3-methyl-4-(2-methylpropyl)thiophen-2-yl]-1,2,4-oxadiazol-3-yl]phenoxy]-2-hydroxypropyl]-2-(methylamino)acetamide Chemical compound C1=C(C)C(OCC(O)CNC(=O)CNC)=C(C)C=C1C1=NOC(C2=C(C(CC(C)C)=CS2)C)=N1 WZOXUNBBCJSFKL-UHFFFAOYSA-N 0.000 claims 1
- OVKKFHCTLCSFTN-UHFFFAOYSA-N n-[3-[2,6-dimethyl-4-[5-[3-methyl-4-(2-methylpropyl)thiophen-2-yl]-1,2,4-oxadiazol-3-yl]phenoxy]-2-hydroxypropyl]-2-hydroxyacetamide Chemical compound CC(C)CC1=CSC(C=2ON=C(N=2)C=2C=C(C)C(OCC(O)CNC(=O)CO)=C(C)C=2)=C1C OVKKFHCTLCSFTN-UHFFFAOYSA-N 0.000 claims 1
- IBQKTKUMDJJLEJ-UHFFFAOYSA-N n-[3-[2,6-dimethyl-4-[5-[3-methyl-4-(2-methylpropyl)thiophen-2-yl]-1,2,4-oxadiazol-3-yl]phenoxy]propyl]-2-hydroxyacetamide Chemical compound CC(C)CC1=CSC(C=2ON=C(N=2)C=2C=C(C)C(OCCCNC(=O)CO)=C(C)C=2)=C1C IBQKTKUMDJJLEJ-UHFFFAOYSA-N 0.000 claims 1
- RJKLHCLWIRTXFZ-UHFFFAOYSA-N n-[3-[2,6-dimethyl-4-[5-[3-methyl-4-(2-methylpropyl)thiophen-2-yl]-1,3,4-oxadiazol-2-yl]phenoxy]-2-hydroxypropyl]-2-hydroxyacetamide Chemical compound CC(C)CC1=CSC(C=2OC(=NN=2)C=2C=C(C)C(OCC(O)CNC(=O)CO)=C(C)C=2)=C1C RJKLHCLWIRTXFZ-UHFFFAOYSA-N 0.000 claims 1
- DEYZDNQSNSGJND-UHFFFAOYSA-N n-[3-[2,6-dimethyl-4-[5-[4-(2-methylpropyl)-3-propylthiophen-2-yl]-1,3,4-oxadiazol-2-yl]phenoxy]-2-hydroxypropyl]-2-hydroxyacetamide Chemical compound CC(C)CC1=CSC(C=2OC(=NN=2)C=2C=C(C)C(OCC(O)CNC(=O)CO)=C(C)C=2)=C1CCC DEYZDNQSNSGJND-UHFFFAOYSA-N 0.000 claims 1
- BVAJHDUZKISYLF-UHFFFAOYSA-N n-[3-[2,6-dimethyl-4-[5-[5-methyl-4-(2-methylpropyl)thiophen-2-yl]-1,2,4-oxadiazol-3-yl]phenoxy]-2-hydroxypropyl]-2-hydroxyacetamide Chemical compound S1C(C)=C(CC(C)C)C=C1C1=NC(C=2C=C(C)C(OCC(O)CNC(=O)CO)=C(C)C=2)=NO1 BVAJHDUZKISYLF-UHFFFAOYSA-N 0.000 claims 1
- USMRGOCLFZPFTE-UHFFFAOYSA-N n-[3-[2-ethyl-6-methyl-4-[5-[3-methyl-4-(2-methylpropyl)thiophen-2-yl]-1,2,4-oxadiazol-3-yl]phenoxy]-2-hydroxypropyl]-2-hydroxyacetamide Chemical compound CC1=C(OCC(O)CNC(=O)CO)C(CC)=CC(C=2N=C(ON=2)C2=C(C(CC(C)C)=CS2)C)=C1 USMRGOCLFZPFTE-UHFFFAOYSA-N 0.000 claims 1
- CJTHMKUIXWSDDO-UHFFFAOYSA-N n-[3-[2-ethyl-6-methyl-4-[5-[5-methyl-4-(2-methylpropyl)thiophen-2-yl]-1,2,4-oxadiazol-3-yl]phenoxy]-2-hydroxypropyl]-2-hydroxyacetamide Chemical compound CC1=C(OCC(O)CNC(=O)CO)C(CC)=CC(C=2N=C(ON=2)C=2SC(C)=C(CC(C)C)C=2)=C1 CJTHMKUIXWSDDO-UHFFFAOYSA-N 0.000 claims 1
- OUCWPDPFPHZXES-UHFFFAOYSA-N n-[3-[4-[3-[3,4-bis(2-methylpropyl)thiophen-2-yl]-3-oxopropyl]-2,6-dimethylphenoxy]-2-hydroxypropyl]-2-hydroxyacetamide Chemical compound CC(C)CC1=CSC(C(=O)CCC=2C=C(C)C(OCC(O)CNC(=O)CO)=C(C)C=2)=C1CC(C)C OUCWPDPFPHZXES-UHFFFAOYSA-N 0.000 claims 1
- NMKMMLLRTFHETQ-UHFFFAOYSA-N n-[3-[4-[5-[3,4-bis(2-methylpropyl)thiophen-2-yl]-1,3,4-oxadiazol-2-yl]-2,6-dimethylphenoxy]-2-hydroxypropyl]-2-hydroxyacetamide Chemical compound CC(C)CC1=CSC(C=2OC(=NN=2)C=2C=C(C)C(OCC(O)CNC(=O)CO)=C(C)C=2)=C1CC(C)C NMKMMLLRTFHETQ-UHFFFAOYSA-N 0.000 claims 1
- AXAPDELCHKZJAZ-UHFFFAOYSA-N n-[3-[4-[5-[3,5-dimethyl-4-(2-methylpropyl)thiophen-2-yl]-1,2,4-oxadiazol-3-yl]-2,6-dimethylphenoxy]-2-hydroxypropyl]-2-hydroxyacetamide Chemical compound CC(C)CC1=C(C)SC(C=2ON=C(N=2)C=2C=C(C)C(OCC(O)CNC(=O)CO)=C(C)C=2)=C1C AXAPDELCHKZJAZ-UHFFFAOYSA-N 0.000 claims 1
- YDRWMNJYXDDCSW-UHFFFAOYSA-N n-[3-[4-[5-[3-ethyl-4-(2-methylpropyl)thiophen-2-yl]-1,3,4-oxadiazol-2-yl]-2,6-dimethylphenoxy]-2-hydroxypropyl]-2-hydroxyacetamide Chemical compound CC(C)CC1=CSC(C=2OC(=NN=2)C=2C=C(C)C(OCC(O)CNC(=O)CO)=C(C)C=2)=C1CC YDRWMNJYXDDCSW-UHFFFAOYSA-N 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 238000011476 stem cell transplantation Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2006050103 | 2006-01-11 | ||
| IBPCT/IB2006/050103 | 2006-01-11 | ||
| PCT/IB2007/050070 WO2007080542A1 (en) | 2006-01-11 | 2007-01-10 | Novel thiophene derivatives as s1p1/edg1 receptor agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009523165A JP2009523165A (ja) | 2009-06-18 |
| JP2009523165A5 true JP2009523165A5 (https=) | 2010-02-25 |
| JP5114430B2 JP5114430B2 (ja) | 2013-01-09 |
Family
ID=37908151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008549960A Expired - Fee Related JP5114430B2 (ja) | 2006-01-11 | 2007-01-10 | Ｓ１ｐ１／ｅｄｇ１受容体アゴニストとしての新規チオフェン誘導体 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8003800B2 (https=) |
| EP (1) | EP1976512B1 (https=) |
| JP (1) | JP5114430B2 (https=) |
| KR (1) | KR101382710B1 (https=) |
| CN (1) | CN101370496B (https=) |
| AR (1) | AR058956A1 (https=) |
| AU (1) | AU2007204121B2 (https=) |
| BR (1) | BRPI0706476A2 (https=) |
| CA (1) | CA2635047C (https=) |
| ES (1) | ES2553345T3 (https=) |
| IL (1) | IL192657A (https=) |
| MY (1) | MY154909A (https=) |
| NO (1) | NO20083462L (https=) |
| NZ (1) | NZ570258A (https=) |
| RU (1) | RU2437877C2 (https=) |
| TW (1) | TWI404706B (https=) |
| WO (1) | WO2007080542A1 (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE447568T1 (de) | 2006-01-24 | 2009-11-15 | Actelion Pharmaceuticals Ltd | Neue pyrinderivate |
| TWI408139B (zh) * | 2006-09-07 | 2013-09-11 | Actelion Pharmaceuticals Ltd | 新穎噻吩衍生物 |
| TWI392671B (zh) * | 2006-09-07 | 2013-04-11 | Actelion Pharmaceuticals Ltd | 吡啶-４-基衍生物 |
| ES2400163T3 (es) * | 2006-09-08 | 2013-04-08 | Actelion Pharmaceuticals Ltd. | Derivados de piridil-3-ilo como agentes de inmunomodulación |
| SG177221A1 (en) * | 2006-12-15 | 2012-01-30 | Abbott Lab | Novel oxadiazole compounds |
| PT2125797E (pt) * | 2007-03-16 | 2014-03-11 | Actelion Pharmaceuticals Ltd | Derivados aminopiridina como agonistas do receptor s1p1/edg1 |
| PE20090305A1 (es) * | 2007-05-22 | 2009-03-15 | Wyeth Corp | Proceso mejorado para la elaboracion de hidrazidas |
| US8598208B2 (en) * | 2007-08-17 | 2013-12-03 | Actelion Pharmaceuticals Ltd. | Pyridine derivatives as S1P1/EDG1 receptor modulators |
| AU2008306886B2 (en) * | 2007-10-04 | 2014-01-16 | Merck Serono S.A. | Oxadiazole diaryl compounds |
| RU2010121969A (ru) | 2007-11-01 | 2011-12-10 | Актелион Фармасьютиклз Лтд (Ch) | Новые производные пиримидина |
| EP2222667B1 (en) * | 2007-12-10 | 2013-02-20 | Actelion Pharmaceuticals Ltd. | Novel thiophene derivatives as agonists of s1p1/edg1 |
| JP5411877B2 (ja) * | 2008-03-06 | 2014-02-12 | アクテリオン ファーマシューティカルズ リミテッド | ピリジン化合物 |
| AU2009220893A1 (en) * | 2008-03-07 | 2009-09-11 | Actelion Pharmaceuticals Ltd | Novel aminomethyl benzene derivatives |
| HRP20130641T1 (en) * | 2008-03-07 | 2013-08-31 | Actelion Pharmaceuticals Ltd. | Pyridin-2-yl derivatives as immunomodulating agents |
| HUE033168T2 (en) | 2008-03-17 | 2017-11-28 | Actelion Pharmaceuticals Ltd | Dosage regimen for selective SIP1 receptor agonist |
| EA019252B1 (ru) | 2008-07-23 | 2014-02-28 | Арена Фармасьютикалз, Инк. | ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ (1,2,3,4-ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛ-3-ИЛ)УКСУСНОЙ КИСЛОТЫ, ПРИМЕНИМЫЕ В ЛЕЧЕНИИ АУТОИММУННЫХ И ВОСПАЛИТЕЛЬНЫХ РАССТРОЙСТВ |
| SI2342205T1 (sl) | 2008-08-27 | 2016-09-30 | Arena Pharmaceuticals, Inc. | Substituirani triciklični kislinski derivati kot agonisti S1P1 receptorja, uporabni v zdravljenju avtoimunskih in vnetnih obolenj |
| CN102471328B (zh) | 2009-07-16 | 2015-04-01 | 埃科特莱茵药品有限公司 | 吡啶-4-基衍生物 |
| US8399451B2 (en) | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
| TW201120016A (en) * | 2009-12-08 | 2011-06-16 | Abbott Lab | Novel oxadiazole compounds |
| SG10201906876PA (en) | 2010-01-27 | 2019-09-27 | Arena Pharm Inc | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
| SG183416A1 (en) | 2010-03-03 | 2012-09-27 | Arena Pharm Inc | Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof |
| WO2011133734A1 (en) | 2010-04-23 | 2011-10-27 | Bristol-Myers Squibb Company | 4 - (5 - isoxazolyl or 5 - pyrrazolyl -1,2,4- oxadiazol - 3 - yl) -mandelic acid amides as sphingosin- 1 - phosphate 1 rreceptor agonists |
| TW201206429A (en) * | 2010-07-08 | 2012-02-16 | Merck Serono Sa | Substituted oxadiazole derivatives |
| EP2619190B1 (en) | 2010-09-24 | 2015-08-12 | Bristol-Myers Squibb Company | Substituted oxadiazole compounds and their use as s1p1 agonists |
| HRP20150919T1 (hr) | 2011-01-19 | 2015-09-25 | Actelion Pharmaceuticals Ltd. | Derivati 2-metoksi-piridin-4-ila |
| MX350891B (es) | 2012-08-17 | 2017-09-22 | Actelion Pharmaceuticals Ltd | Proceso para la preparacion de (2z,5z)-5-(3-cloro-4-((r)-2,3-dihid roxipropoxi) bencilideno)-2-(propilimino)-3-(o-tolil) tiazolidin-4-ona y el intermediario usado en dicho proceso. |
| MX386419B (es) | 2015-01-06 | 2025-03-18 | Arena Pharm Inc | Metodos de condiciones de tratamiento relacionadas con el receptor s1p1. |
| MX393708B (es) | 2015-03-06 | 2025-03-24 | Agc Inc | Metodo para producir derivado de 1,2,4-oxadiazol. |
| BR112017024785B1 (pt) | 2015-05-20 | 2022-05-17 | Idorsia Pharmaceuticals Ltd | Forma cristalina do composto (s)-3-{4-[5-(2-ciclopentil-6-metoxi-piridin-4-il)-[1,2,4] oxadiazol-3- il]-2-etil-6-metilfenoxi}-propano-1,2-diol, composição farmacêutica, e, uso |
| US10111841B2 (en) | 2015-06-19 | 2018-10-30 | University Of South Florida | Stabilization of alcohol intoxication-induced cardiovascular instability |
| EP3939965A1 (en) | 2015-06-22 | 2022-01-19 | Arena Pharmaceuticals, Inc. | Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in sipi receptor-associated disorders |
| MA47504A (fr) | 2017-02-16 | 2019-12-25 | Arena Pharm Inc | Composés et méthodes de traitement de l'angiocholite biliaire primitive |
| WO2018151834A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations |
| ES2987794T3 (es) | 2018-06-06 | 2024-11-18 | Arena Pharm Inc | Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1 |
| CN112955431A (zh) | 2018-09-06 | 2021-06-11 | 艾尼纳制药公司 | 可用于治疗自身免疫性病症和炎性病症的化合物 |
| US11014897B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof |
| US11186556B1 (en) | 2018-10-16 | 2021-11-30 | Celgene Corporation | Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof |
| US11014940B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Thiazolidinone and oxazolidinone compounds and formulations |
| US11013723B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms of a thiazolidinone compound, compositions and methods of use thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7686891A (en) | 1990-04-05 | 1991-10-30 | American National Red Cross, The | A protein family related to immediate-early protein expressed by human endothelial cells during differentiation |
| DE19643037A1 (de) * | 1996-10-18 | 1998-04-23 | Boehringer Ingelheim Kg | Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel |
| WO1999046277A1 (en) | 1998-03-09 | 1999-09-16 | Smithkline Beecham Corporation | HUMAN EDG-1c POLYNUCLEOTIDES AND POLYPEPTIDES AND METHODS OF USE |
| RU2233839C1 (ru) * | 2000-07-13 | 2004-08-10 | Санкио Компани, Лимитед | Производные аминоспиртов, фармацевтическая композиция, способ профилактики или лечения, промежуточные соединения и способ получения промежуточных соединений |
| ATE448193T1 (de) * | 2002-01-18 | 2009-11-15 | Merck & Co Inc | ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß |
| US7479504B2 (en) | 2002-01-18 | 2009-01-20 | Merck & Co., Inc. | Edg receptor agonists |
| US20050070506A1 (en) * | 2002-01-18 | 2005-03-31 | Doherty George A. | Selective s1p1/edg1 receptor agonists |
| JP2005533058A (ja) | 2002-06-17 | 2005-11-04 | メルク エンド カムパニー インコーポレーテッド | Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート |
| WO2004035538A1 (en) * | 2002-10-15 | 2004-04-29 | Merck & Co., Inc. | Process for making azetidine-3-carboxylic acid |
| US20060252741A1 (en) | 2003-05-15 | 2006-11-09 | Colandrea Vincent J | 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists |
| TW200505416A (en) * | 2003-08-12 | 2005-02-16 | Mitsubishi Pharma Corp | Bi-aryl compound having immunosuppressive activity |
| CN1859908A (zh) * | 2003-10-01 | 2006-11-08 | 默克公司 | 作为s1p受体激动剂的3,5－芳基、杂芳基或环烷基取代的－1,2,4－噁二唑类化合物 |
| US7605171B2 (en) | 2003-12-17 | 2009-10-20 | Merck & Co., Inc. | (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists |
| EP1760071A4 (en) * | 2004-06-23 | 2008-03-05 | Ono Pharmaceutical Co | COMPOUND WITH S1P RECEPTOR BINDING ABILITY AND USE THEREOF |
| WO2006010379A1 (en) * | 2004-07-29 | 2006-02-02 | Actelion Pharmaceuticals Ltd. | Novel thiophene derivatives as immunosuppressive agents |
| BRPI0609668A2 (pt) * | 2005-03-23 | 2011-10-18 | Actelion Pharmaceuticals Ltd | composto, composição farmacêutica, e, uso de um composto |
| US7723378B2 (en) * | 2005-03-23 | 2010-05-25 | Actelion Pharmaceuticals Ltd. | Hydrogenated benzo (C) thiophene derivatives as immunomodulators |
| KR20080002850A (ko) * | 2005-03-23 | 2008-01-04 | 액테리온 파마슈티칼 리미티드 | 신규한 티오펜 유도체 |
| BRPI0612028A2 (pt) | 2005-06-08 | 2010-10-13 | Novartis Ag | oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p |
| EP1896446A1 (en) | 2005-06-24 | 2008-03-12 | Actelion Pharmaceuticals Ltd. | Novel thiophene derivatives |
| GB0601744D0 (en) | 2006-01-27 | 2006-03-08 | Novartis Ag | Organic compounds |
| SG177221A1 (en) | 2006-12-15 | 2012-01-30 | Abbott Lab | Novel oxadiazole compounds |
| WO2008091967A1 (en) | 2007-01-26 | 2008-07-31 | Smithkline Beecham Corporation | Chemical compounds |
| EP2222667B1 (en) * | 2007-12-10 | 2013-02-20 | Actelion Pharmaceuticals Ltd. | Novel thiophene derivatives as agonists of s1p1/edg1 |
-
2007
- 2007-01-05 TW TW096100513A patent/TWI404706B/zh not_active IP Right Cessation
- 2007-01-09 AR ARP070100083A patent/AR058956A1/es unknown
- 2007-01-10 AU AU2007204121A patent/AU2007204121B2/en not_active Ceased
- 2007-01-10 MY MYPI20082557A patent/MY154909A/en unknown
- 2007-01-10 JP JP2008549960A patent/JP5114430B2/ja not_active Expired - Fee Related
- 2007-01-10 CN CN2007800022066A patent/CN101370496B/zh not_active Expired - Fee Related
- 2007-01-10 WO PCT/IB2007/050070 patent/WO2007080542A1/en not_active Ceased
- 2007-01-10 KR KR1020087018081A patent/KR101382710B1/ko not_active Expired - Fee Related
- 2007-01-10 ES ES07700562T patent/ES2553345T3/es active Active
- 2007-01-10 CA CA2635047A patent/CA2635047C/en not_active Expired - Fee Related
- 2007-01-10 US US12/160,520 patent/US8003800B2/en not_active Expired - Fee Related
- 2007-01-10 EP EP07700562.7A patent/EP1976512B1/en active Active
- 2007-01-10 RU RU2008132802/04A patent/RU2437877C2/ru not_active IP Right Cessation
- 2007-01-10 BR BRPI0706476-4A patent/BRPI0706476A2/pt not_active IP Right Cessation
- 2007-01-10 NZ NZ570258A patent/NZ570258A/en not_active IP Right Cessation
-
2008
- 2008-07-07 IL IL192657A patent/IL192657A/en not_active IP Right Cessation
- 2008-08-08 NO NO20083462A patent/NO20083462L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009523165A5 (https=) | ||
| RU2437877C2 (ru) | Новые производные тиофена в качестве агонистов рецептора s1p1/edg1 | |
| JP5036923B1 (ja) | ピリジン−４−イル誘導体 | |
| HRP20120962T1 (hr) | Derivati tiofena kao agonisti s1p1/edg1 receptora | |
| HRP20130181T1 (hr) | Derivati piridin-4-ila kao sredstva imunomodulacije | |
| RU2009112726A (ru) | Производные пиридин-3-ила в качестве иммуномодулирующих агентов | |
| JP5963823B2 (ja) | Ｓ１ｐ受容体モジュレーターおよびそれらの使用 | |
| KR101781233B1 (ko) | 스핑고신 1 포스페이트 수용체 조절자 및 카이랄 합성 방법 | |
| CN102239164B (zh) | 2h-色烯化合物及其衍生物 | |
| CN104672115B (zh) | 作为有生理学价值的硝酰氧基供体的n-羟基磺酰胺衍生物 | |
| DK2776425T3 (en) | NEW cyclohexylamine WITH beta2-adrenergic agonist and M3 MUSKARINANTAGONISTAKTIVITETER | |
| RU2010121969A (ru) | Новые производные пиримидина | |
| RU2010128006A (ru) | Производные тиофена в качестве агонистов sipi/edgi | |
| HRP20140335T1 (hr) | Derivati amino-piridina kao agonisti s1p1/edg1-receptora | |
| CA2606087A1 (en) | Novel oxadiazole derivatives and their medical use | |
| TWI410410B (zh) | Phenylacetic acid compounds | |
| BR122017003181A2 (pt) | composto inibidor de trk, composição farmacêutica e medicamento compreendendo dito composto e seu uso para profilaxia e/ou terapia de doença relacionada à trk e/ou para inibir trk | |
| CA2825172A1 (en) | Indole derivative and pharmacologically acceptable salt of same | |
| JP2009538358A (ja) | 脂肪酸アミド加水分解酵素のオキサゾリルピペリジン・モジュレーター | |
| JPWO2016153023A1 (ja) | 新規オキサジアゾール誘導体及びこれを含有する医薬 | |
| JP2010513434A5 (https=) | ||
| JP2013520490A (ja) | オキサジアゾール化合物、ならびにそれらの製造および用途 | |
| RU2010140854A (ru) | Пиридин-2-ильные производные в качестве иммуномодулирующих агентов | |
| CN103380112A (zh) | 作为s1p受体调节剂的吲哚衍生物 | |
| JP2010519278A5 (https=) |